A phase 1/2 trial of WJB001 in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05773820 by Wigen Biomedicine Technology (Shanghai) Co., Ltd., with 210 participants planned, started 2023-05-05 and due to reach its primary completion in 2026-08-08. Interventions recorded: WJB001.
Shares WJB001, Wigen Biomedicine Technology (Shanghai), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.